Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Axsome Therapeutics Inc (AXSM)
NASDAQ:AXSM
Axsome Therapeutics (AXSM) Stock Price & Analysis
1,764 Followers
AXSM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$55.02 - $98.40
Previous Close$71.1
Volume498.86K
Average Volume (3M)733.61K
Market Cap
$3.37B
Enterprise Value$3.17B
Total Cash (Recent Filing)$386.19M
Total Debt (Recent Filing)$186.37M
Price to Earnings (P/E)-13.7
Beta0.08
Next Earnings
May 06, 2024EPS Estimate
-$1.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.20
Shares Outstanding47,374,375
10 Day Avg. Volume594,371
30 Day Avg. Volume733,605
Standard Deviation0.31
R-Squared0.04
Alpha0.05
Financial Highlights & Ratios
Price to Book (P/B)25.60
Price to Sales (P/S)44.97
Price to Cash Flow (P/CF)-26.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue11.74
Enterprise Value/Gross Profit10.80
Enterprise Value/Ebitda-14.49
Forecast
1Y Price Target
$121.80Price Target Upside71.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
Axsome Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical Progress And Label ExpansionAxsome Therapeutics announced the initiation of the ENGAGE Phase 3 trial of solriamfetol, an investigational treatment for binge-eating disorder in adults.
Drug Efficacy And Market PotentialCaplyta's efficacy and safety data came in stronger than anticipated which could influence the market's view on the drug's competitive potential.
Market Entry And GrowthAuvelity has had a relatively excellent start since its product launch, indicating a strong market entry.
Bears Say
Clinical Trial ConcernsDespite achieving the primary endpoint, there was a high placebo response in the SYMPHONY study, which may cast doubts on AXS-12's efficacy.
CompetitionCaplyta could be positioned directly against Auvelity in the post-SSRI/post-SNRI MDD setting, introducing potential competition.
Operational IssuesA cyber-attack at Change Healthcare has made it difficult for prescriptions to get filled, potentially affecting Auvelity's sales figures.
---
Ownership Overview
1.37% Insiders
14.89% Mutual Funds
13.03% Other Institutional Investors
70.71% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AXSM FAQ
What was Axsome Therapeutics Inc’s price range in the past 12 months?
Axsome Therapeutics Inc lowest stock price was $55.02 and its highest was $98.40 in the past 12 months.
What is Axsome Therapeutics Inc’s market cap?
Currently, no data Available
When is Axsome Therapeutics Inc’s upcoming earnings report date?
Axsome Therapeutics Inc’s upcoming earnings report date is May 06, 2024 which is in 13 days.
How were Axsome Therapeutics Inc’s earnings last quarter?
Axsome Therapeutics Inc released its earnings results on Feb 20, 2024. The company reported -$2.08 earnings per share for the quarter, missing the consensus estimate of -$1.171 by -$0.909.
Is Axsome Therapeutics Inc overvalued?
According to Wall Street analysts Axsome Therapeutics Inc’s price is currently Undervalued.
Does Axsome Therapeutics Inc pay dividends?
Axsome Therapeutics Inc does not currently pay dividends.
What is Axsome Therapeutics Inc’s EPS estimate?
Axsome Therapeutics Inc’s EPS estimate is -$1.18.
How many shares outstanding does Axsome Therapeutics Inc have?
Axsome Therapeutics Inc has 47,374,374 shares outstanding.
What happened to Axsome Therapeutics Inc’s price movement after its last earnings report?
Axsome Therapeutics Inc reported an EPS of -$2.08 in its last earnings report, missing expectations of -$1.171. Following the earnings report the stock price went down -12.574%.
Which hedge fund is a major shareholder of Axsome Therapeutics Inc?
Among the largest hedge funds holding Axsome Therapeutics Inc’s share is Fairmount Funds Management Llc. It holds Axsome Therapeutics Inc’s shares valued at 188M.
---
Axsome Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$121.80 (71.31% Upside)
$121.80 (71.31% Upside)
Blogger Sentiment
Bullish
AXSM Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 557.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 0.8%
Last 30 Days ▼ 0.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-2.49%
12-Months-Change
Fundamentals
Return on Equity
-159.21%
Trailing 12-Months
Asset Growth
77.46%
Trailing 12-Months
Company Description
Axsome Therapeutics Inc
Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies for the management of central nervous system disorders. Its product candidates include AXS-02 and AXS-06 which are developing for multiple indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.
---
AXSM Company Deck
---
AXSM Earnings Call
Q4 2024
0:00 / 0:00
---
AXSM Stock 12 Months Forecast
Average Price Target
$121.80
▲(71.31% Upside)
Technical Analysis
AnaptysBio
―
Anavex Life Sciences
―
Intra-Cellular Therapies
―
Karyopharm Therapeutics
―
Best Analysts Covering AXSM
1 Year
1 Year Success Rate
16/25 ratings generated profit
1 Year Average Return
+35.20%
reiterated a buy rating 29 days ago
Copying Marc Goodman's trades and holding each position for 1 Year would result in 64.00% of your transactions generating a profit, with an average return of +35.20% per trade.
---